Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

Related Articles by Review for PubMed (Select 21063011)

1.

Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices.

Resnic FS, Gross TP, Marinac-Dabic D, Loyo-Berrios N, Donnelly S, Normand SL, Matheny ME.

JAMA. 2010 Nov 10;304(18):2019-27. doi: 10.1001/jama.2010.1633.

PMID:
21063011
2.

Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.

Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K.

Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Review.

PMID:
19952925
3.

Unique device identifiers for coronary stent postmarket surveillance and research: a report from the Food and Drug Administration Medical Device Epidemiology Network Unique Device Identifier demonstration.

Tcheng JE, Crowley J, Tomes M, Reed TL, Dudas JM, Thompson KP, Garratt KN, Drozda JP Jr; MDEpiNet UDI Demonstration Expert Workgroup.

Am Heart J. 2014 Oct;168(4):405-413.e2. doi: 10.1016/j.ahj.2014.07.001. Epub 2014 Jul 7. Review.

PMID:
25262248
4.

But doctor, it's my hip!: the fate of failed medical devices.

Fielder JH, Black J.

Kennedy Inst Ethics J. 1995 Jun;5(2):113-31. Review.

PMID:
10172331
5.

Registries of implantable medical devices in Europe.

Niederländer C, Wahlster P, Kriza C, Kolominsky-Rabas P.

Health Policy. 2013 Nov;113(1-2):20-37. doi: 10.1016/j.healthpol.2013.08.008. Epub 2013 Sep 4. Review.

PMID:
24075007
6.

Approval of high-risk medical devices in the US: implications for clinical cardiology.

Rome BN, Kramer DB, Kesselheim AS.

Curr Cardiol Rep. 2014;16(6):489. doi: 10.1007/s11886-014-0489-0. Review.

7.

Current challenges for clinical trials of cardiovascular medical devices.

Zannad F, Stough WG, Piña IL, Mehran R, Abraham WT, Anker SD, De Ferrari GM, Farb A, Geller NL, Kieval RS, Linde C, Redberg RF, Stein K, Vincent A, Woehrle H, Pocock SJ.

Int J Cardiol. 2014 Jul 15;175(1):30-7. doi: 10.1016/j.ijcard.2014.05.021. Epub 2014 May 16. Review.

PMID:
24861254
8.

Part II: Sealing holes in the safety net.

Peterson ED, Hirshfeld JW Jr, Ferguson TB, Kramer JM, Califf RM, Kessler LG.

Am Heart J. 2004 Jun;147(6):985-90. Review. No abstract available.

PMID:
15199344
9.

Postmarketing safety of biologics and biological devices.

Woo EJ.

Spine J. 2014 Mar 1;14(3):560-5. doi: 10.1016/j.spinee.2013.09.056. Epub 2013 Dec 14. Review.

PMID:
24342704
10.

Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis.

Vardi M, Yeh RW, Herzog CA, Winkelmayer WC, Setoguchi S, Charytan DM.

Clin J Am Soc Nephrol. 2013 Dec;8(12):2213-20. doi: 10.2215/CJN.05130513. Epub 2013 Aug 22. Review.

11.

Evidence behind FDA alerts for drugs with adverse cardiovascular effects: implications for clinical practice.

Rackham DM, C Herink M, Stevens IG, Cardoza NM, Singh H.

Pharmacotherapy. 2014;34(4):358-72. doi: 10.1002/phar.1381. Epub 2013 Dec 18. Review.

PMID:
24347043
12.

Using registries to identify adverse events in rheumatic diseases.

Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI.

Pediatrics. 2013 Nov;132(5):e1384-94. doi: 10.1542/peds.2013-0755. Epub 2013 Oct 21. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk